Senya Therapeutics was established to develop a portfolio of therapeutics targeting Leucine-rich alpha-2 glycoprotein 1 (LRG1), a key driver of chronic diseases through its impact on inflammatory and fibrotic processes.

Senya operates as the trading name of LRG1 Limited, a UK-registered company. Originally founded in 2019 as a spinout from University College London (UCL), the company was previously known as Panangium Therapeutics, focusing on LRG1-targeting therapies for vascular disorders.

Subsequent research revealed LRG1’s broader role in chronic diseases beyond vasculature, influencing inflammation and tissue remodeling. In response, LRG1 Limited rebranded as Senya Therapeutics, expanding its research scope to include kidney diseases, cancer and more. Senya is a leading anti-LRG1 technology platform company.